Biohaven enters a significant research collaboration with Merus, enhancing its capabilities in developing novel bispecific antibody drug conjugates, which could lead to innovative cancer therapies.

Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the development ...

This article is based on a poster originally authored by An Ouyang, Spencer Chiang and Chao Wang. Antibody-drug conjugates (ADCs) are a new class of anti-cancer therapeutics that are both novel and ...

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such ...

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

Glycosite-specific conjugation has emerged as a gold standard for developing next-generation Antibody-Drug Conjugates (ADCs) and other XDCs. However, most existing approaches are hindered by ...

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are investing in capacity to meet the companies’ manufacturing needs.